Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report.
In recent years, the use of vasopressin analogues in the treatment of hepatorenal syndrome has become an effective therapeutic strategy leading to improved survival and often allowing the completion of liver transplantation. Terlipressin, in particular, has proven to be safe and effective. Due to the limited number of patients treated so far, it is, however, difficult to draw any definite conclusions on the optimal dosage and on the occurrence of side-effects in these patients. The case is reported of an ascitic cirrhotic patient who developed spontaneous bacterial peritonitis followed by a type-I hepatorenal syndrome. Treatment with terlipressin boluses (0.5 mg/4 h) associated with albumin infusion was then started. The course of the disease was monitored by clinical and laboratory means. After 10 boluses of terlipressin, rectorrhagia and severe ischaemic complications involving the skin of the abdomen, lower limbs, scrotus, and penis, occurred. These ischaemic complications improved after terlipressin withdrawal, while renal failure evolved leading to the patient's death. This case report shows that, in patients with type-I hepatorenal syndrome, the use of terlipressin, even at low dosages, may induce life-threatening ischaemic complications and, moreover, suggests that the recent occurrence of spontaneous bacterial peritonitis, even if properly treated, may significantly increase the risk of major ischaemic complications.
Vaccaro
F
F
Department of Clinical Medicine, University of Rome 'La Sapienza', Viale dell'Università 37, 00185 Rome, Italy. francesco.vaccaro@uniroma1.it
Giorgi
A
A
Riggio
O
O
De Santis
A
A
Laviano
A
A
Rossi-Fanelli
F
F
D000368:Aged; D001201:Ascites / Q000209:etiology; D001424:Bacterial Infections / Q000150:complications*; D004305:Dose-Response Relationship, Drug; D017809:Fatal Outcome; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced*; D006530:Hepatorenal Syndrome / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007262:Infusions, Intravenous; D007511:Ischemia / Q000139:chemically induced*; D008103:Liver Cirrhosis / Q000150:complications; D008236:Lypressin / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D008297:Male; D010538:Peritonitis / Q000382:microbiology*; D012007:Rectum; D012709:Serum Albumin / Q000008:administration & dosage; D000077585:Terlipressin; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000009:adverse effects*
D012709:Serum Albumin; D014662:Vasoconstrictor Agents; D008236:Lypressin; D000077585:Terlipressin